Immunologic Research

, Volume 24, Issue 1, pp 13–29

The HMG I proteins

Dynamic roles in gene activation, development, and tumorigenesis
  • Franklin Liu
  • Kai-yin Chau
  • Paola Arlotta
  • Santa Jerenry Ono
Article

Abstract

The high mobility group I, Y, and I-C proteins are low-molecularweight, nonhistone chromosomal proteins that play a general role modulating gene expression during development and the immune response. Consistent with their role in early development, all three proteins are expressed at high levels during embryogenesis, and their expression is markedly diminished in differentiated cells. Exceptions to the general repression of these genes in adult tissues involve (1) A burst of synthesis of the HMG I protein during the immune response (during lymphocyte activation and preceding cytokine/adhesion molecule gene expression), (2) A constitutive expression of the HMG I and Y proteins in photoreceptor cells, and (3) Derepression of HMG I, Y, and often I-C expression in neoplastic cells. Work from several laboratorie shasnow uncovered how these proteins participate in gene activation: (1) By altering the chromatin structure around an inducible gene—and thus influencing accessibility of the locus to regulatory proteins—(2) By facilitating the loading of transcription factors onto the promoters and (3) By bridging adjacent transcription factors on a promoter via protein/protein interactions. Despite the similar structures and biochemical properties of the three proteins, the work has also provided clues to a division of labor between these proteins. HMG I and Y have demonstrable roles in enhanceo some formation, whereas HMG I-C has a specific role in adipogenesis. C-terminal truncations of HMG I-C and wild-type HMG Y appear to function in a manner analogous to oncogenes as assessed by cellular transformation assays and transgenic mice. Future work should clearly define the similarities and differences in the biological roles of the three proteins, and should evolve to include attempts at pharmaceutical intervention in disease, based upon structural information concerning HMG I interactions with DNA and with regulatory proteins.

Key Words

HMG I proteins Gene expression Cancer Development Adipogenesis Lipomas 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Johns EW (ed): History definitions and problems: In The HMG Chromosomal Proteins, London, 1982; p 1–7.Google Scholar
  2. 2.
    Lund T, Holtlund J, Fredriksen M, Laland SG: On the presence of two new high mobility group-like proteins in HeLa S3 cells. FEBS Lett 1983;152:163–167.PubMedGoogle Scholar
  3. 3.
    Strauss F, Varshavsky A: A protein binds to a satellite DNA repeat at three specific sites that would be brought into mutual proximity by DNA folding in the nucleosome. Cell 1984;37:889–901.PubMedGoogle Scholar
  4. 4.
    Bewley CA, Gronenborn AM, Clore GM: Minor groove-binding architectural proteins: structure, function, and DNA recognition. Annu Rev Biophys Biomol Struct 1998;27:105–131.PubMedGoogle Scholar
  5. 5.
    Bustin M, Lehn DA, Landsman D: Structural features of the HMG chromosomal proteins and their genes. Biochim Biophys Acta 1990;1049:231–243.PubMedGoogle Scholar
  6. 6.
    Bustin M, Reeves R: High-mobility-group chromosomal proteins: architectural components that facilitate chromatin function. Prog Nucleic Acid Res Mol Biol 1996;54:35–100.PubMedCrossRefGoogle Scholar
  7. 7.
    Wunderlich V, Bottger M: High-mobility-group proteins and cancer—an emerging link [editorial]. J Cancer Res Clin Oncol 1997;123:133–140.PubMedGoogle Scholar
  8. 8.
    Shannon MF, Himes SR, Attema J: A role for the architectural transcription factors HMGI (Y) incytokine gene transcription in T cells. Immunol Cell Biol 1998;76: 461–466.PubMedGoogle Scholar
  9. 9.
    Zhou X, Chada K: HMGI family proteins: architectural transcription factors in mammalian development and cancer. Keio J Med 1998;47:73–77.PubMedGoogle Scholar
  10. 10.
    Hess JL: Chromosomal translocations in benign tumors: the HMGI proteins. Am J Clin Pathol 1998; 109:251–261.PubMedGoogle Scholar
  11. 11.
    Goodwin G: The high mobility group protein, HMGI-C. Int J Biochem Cell Biol 1998;30: 761–766.PubMedGoogle Scholar
  12. 12.
    Tallini G, Dal Cin P: HMGI (Y) and HMGI-C dysregulation: a common occurrence in human tumors. Adv Anat Pathol 1999;6: 237–246.PubMedGoogle Scholar
  13. 13.
    Bianchi ME, Beltrame M: EMBO Reports 2000;1:109–119.PubMedGoogle Scholar
  14. 14.
    Reeves R: Structure and function of the HMGI(Y) family, of architectural transcription factors [In Process Citation]. Environ Health Perspect 2000;108 Suppl 15:803–809.PubMedGoogle Scholar
  15. 15.
    Johnson KR, Lehn DA, Elton TS, Barr PJ, Reeves R: Complete murine cDNA sequence, genomic structure, and tissue expression of the high mobility group protein HMG-I(Y). J Biol Chem 1988;263: 18,338–18,342.Google Scholar
  16. 16.
    Johnson KR, Lehn DA, Reeves R: Alternative processing of mRNAs encoding mammalian chromosomal high-mobility-group proteins HMG-I and HMG-Y. Mol Cell Biol 1989;9:2114–2123.PubMedGoogle Scholar
  17. 17.
    Friedmann M, Holth LT, Zoghbi HY, Reeves R: Organization, inducible-expression and chromosome localization of the human HMG-I(Y) nonhistone protein gene. Nucleic Acids Res 1993; 21:4259–4267.PubMedGoogle Scholar
  18. 18.
    Manfioletti G, Giancotti V, Bandiera A, et al.: cDNA cloning of the HMGI-C phosphoprotein, a nuclear protein associated with neoplastic and undifferentiated phenotypes. Nucleic Acids Res 1991;19:6793–6797.PubMedGoogle Scholar
  19. 19.
    Patel UA, Bandiera A, Manfioletti G, Giancotti V, Chau KY, Crane-Robinson C: Expression and cDNA cloning of human HMGI-C phosphoprotein. Biochem Biophys Res Commun 1994;201:63–70.PubMedGoogle Scholar
  20. 20.
    Chau KY, Patel UA, Lee KL, Lam HY, Crane-Robinson C: The gene for the human architectural transcription factor HMGI-C consists of five exons earchcoding for a distinct functional element. Nucleic Acids Res 1995;23:4262–4266.PubMedGoogle Scholar
  21. 21.
    Manfioletti G, Rustighi A, Mantovani F, Goodwin GH, Giancotti V: Isolation and characterization of the gene coding for murine high-mobility-group protein HMGI-C. Gene 1995;167:249–253.PubMedGoogle Scholar
  22. 22.
    Johnson KR, Cook SA, Davisson MT: Chromosomal localization of the murine gene and two related sequences encoding high-mobility-group I and Y proteins. Genomics 1992;12:503–509.PubMedGoogle Scholar
  23. 23.
    Liu J, Chada K: Genomic structure and expression of the murine Hmgi(y) gene. Gene 2000;246: 197–207.PubMedGoogle Scholar
  24. 24.
    Ashar HR, Fejzo MS, Tkachenko A, et al.: Disruption of the architectural factor HMGI-C: DNA-binding AT book motifs fused in lipomas to distinct transcriptional regulatory domains. Cell 1995; 82:57–65.PubMedGoogle Scholar
  25. 25.
    Schoenmakers EF, Wanschura S, Mols R, Bullerdiek J, Van den Berghe H, Van de Ven WJ: Recurrent rearrangements in the high mobility group protein gene, HMGI-C, in benign messenchymal tumours. Nat Genet 1995;10: 436–444.PubMedGoogle Scholar
  26. 26.
    Ashar HR, Cherath L, Przybysz KM, Chada K: Genomic characterization of human HMGIC, a member of the accessory transcription factor family found at translocation breakpoints in lipomas. Genomics 1996;31: 207–214.PubMedGoogle Scholar
  27. 27.
    Zhou X, Benson KF, Ashar HR, Chada K: Mutation responsible for the mouse pygmy phenotype in the developmentally regulated factor HMGI-C [see comments]. Nature 1995;376:771–774.PubMedGoogle Scholar
  28. 28.
    Cmarik JL, Li Y, Ogram SA, Min H, Reeves R, Colburn NH: Tumor promoter induces high mobility group HMG-Y protein expression in transformation-sensitive but not-resistant cells. Oncogene 1998;16: 3387–3396.PubMedGoogle Scholar
  29. 29.
    Banks GC, Li Y, Reeves R: Differential in vivo modifications of the HMGI(Y) nonhistone chromatin proteins modulate nucleosome and DNA interactions [In Process Citation]. Biochemistry 2000;39:8333–8346.PubMedGoogle Scholar
  30. 30.
    Chakarov S, Chakalova L, Tencheva Z, Ganev V, Angelova A: Morphine treatment affects the regulation of high mobility group I-type chromosomal phosphoproteins in C6 glioma cells. Life Sci 2000;66:1725–1731.PubMedGoogle Scholar
  31. 31.
    Piekieko A, Drung A, Rogalla P, et al.: Distinct organization of DNA complexes of various HMGI/Y family proteins and their modulation upon mitotic phosphorylation. J Biol Chem 2000;Oct. 16.Google Scholar
  32. 32.
    Reeves R, Nissen MS: The A.T-DNA-binding domain of mammalian high mobility group 1 chromosomal proteins. A novel peptide motif for recognizing DNA structure. J Biol Chem 1990;265: 8573–8582.PubMedGoogle Scholar
  33. 33.
    Bustin M: Regulation of DNA-dependent activities by the functional motifs of the high-mobility-group chromosomal proteins. Mol Cell Biol 1999;19: 5237–5246.PubMedGoogle Scholar
  34. 34.
    Huth JR, Bewley CA, Nissen MS, et al.: The solution structure of an HMG-I(Y)-DNA complex defines a new architectural minor groove binding motif. Nat Struct Biol 1997;4:657–665.PubMedGoogle Scholar
  35. 35.
    Reeves R, Nissen MS: Interaction of high mobility group-I (Y) non-histone proteins with nucleosome core particles. J Biol Chem 1993;268:21,137–21,146.Google Scholar
  36. 36.
    Claus P, Schulze E, Wisniewski JR: Insect proteins homologous to mammalian high mobility group proteins I/Y (HMG I/Y). Characteriation and binding to linear and four-way juction DNA. J Biol Chem 1994;269:33,042–33,048.Google Scholar
  37. 37.
    Hill DA, Reeves R: Competition between HMG-I(Y), HMG-I and histone H1 on four-way junction DNA. Nucleic Acids Res 1997;25: 3523–3531.PubMedGoogle Scholar
  38. 38.
    Zhao K, Kas E, Gonzalez E, Laemmli UK: SAR-dependent mobilization of histone H1 by HMG-I/Y in vitro: HMG-I/Y is enriched H1-depleted chromatin. Embo J 1993;12:3237–3247.PubMedGoogle Scholar
  39. 39.
    Reeves R, Wolffe AP: Substrate structure influences binding of the non-histone protein HMG-I(Y) to free nucleosomal DNA. Biochemistry 1996;35:5063–5074.PubMedGoogle Scholar
  40. 40.
    Hill DA, Pedulla ML, Reeves R: Directional binding of HMG-I(Y) on four-way junction DNA and the molecular basis for competitive binding with HMG-I and histone H1. Nucleic Acids Res 1999;27: 2135–2144.PubMedGoogle Scholar
  41. 41.
    Lanahan A, Williams JB, Sanders LK, Nathans D: Growth factor-induced delayed early response genes. Mol Cell Biol 1992;12: 3919–3929.PubMedGoogle Scholar
  42. 42.
    Chin MT, Pellacani A, Hsieh CM, et al.: Induction of high mobility group 1 architectural transcription factors in proliferating vascular smooth muscle in vivo and in vitro. J Mol Cell Cardiol 1999;31: 2199–2205.PubMedGoogle Scholar
  43. 43.
    Wood LJ, Mukherjee M, Dolde CE, et al.: HMG-I/Y, a new c-Myc target gene and potential oncogene. Mol Cell Biol 2000;20:5490–5502.PubMedGoogle Scholar
  44. 44.
    Pellacani A, Chin MT, Wiesel P, et al.: Induction of high mobility group-I(Y) protein by endotoxin and interleukin-I beta in vascular smooth muscle cells. Role in activation of inducible nitric oxide synthase. J Biol Chem 1999;274: 1525–1532.PubMedGoogle Scholar
  45. 45.
    Pellacani A, Wiese IP, Razavi S, et al.: Down-regulation of high mobility group-I(Y) protein contributes to the inhibition of nitric oxide synthase 2 by transforming growth factor-betal. J Biol Chem 2001;276:1658–1659.Google Scholar
  46. 46.
    Li D, Lin HH, McMahon M, Ma H, Ann DK: Oncogenic raf-1 induces the expression of non-histone chromosomal architectural protein HMG I-C via a p44/p42 mitogen-activated protein kinase-dependent pathway in salivary epithelial cells. J Biol Chem 1997;272:25,062–25,070.Google Scholar
  47. 47.
    Chuvpilo S, Schomberg C, Gerwig R, et al.: Multiple closely-linked NFAT/octamer and HMG I(Y) binding sites are part of the interleukin-4 promoter. Nucleic Acids Res 1993;21:5694–5704.PubMedGoogle Scholar
  48. 48.
    Palvimo J, Linnala-Kankkumen A: Identification of sites on chromosomal protein HMG-I phosphorylated by casein kinase II. FEBS Lett 1989;257:101–104.PubMedGoogle Scholar
  49. 49.
    Ferranti P, Malorni A, Marino G, et al.: Masspectrometric analysis of the HMGY protein from Lewis lung carcinoma. Identification of phosphorylationsites. J Biol Chem 1992;267:22,486–22,489.Google Scholar
  50. 50.
    Nissen MS, Langan TA, Reeves R: Phosphorylation by cdc 2 kinase modulates DNA binding activity of high mobility group 1 nonhistone chromatin protein. J Biol Chem 1991;266:19,945–19,952.Google Scholar
  51. 51.
    Reeves R, Langan TA, Nissen MS: Phosphorylation of the DNA-binding domain of nonhistone high-mobility group I protein by cdc2 kinase: reduction of binding affinity. Proc Natl Acad Sci USA 1991;88:1671–1675.PubMedGoogle Scholar
  52. 52.
    Schwanbeck R, Wisniewski JR: Cdc2 and mitogen-activated protein kinases modulate DNA binding properties of the putative transcriptional regulator Chironomus high mobility group protein I. J Biol Chem 1997;272:27,476–27,483.Google Scholar
  53. 53.
    Schwanbeck R, Manfioletti G, Wisniewski JR: Architecture of high mobility group protein I-C. DNA complex and its perturbation upon phosphorylation by Cdc2 kinase. J Biol Chem 2000;275: 1793–1801.PubMedGoogle Scholar
  54. 54.
    Xiao DM, Pak JH, Wang X, et al.: Phosphorylation of HMG-I by protein kinase C attenuates its binding affinity to the promoter regions of protein kinase C gamma and neurogranin/RC3 genes. J Neurochem 2000;74:392–399.PubMedGoogle Scholar
  55. 55.
    Munshi N, Merika M, Yie J, Senger K, Chen G, Thanos D: Acetylation of HMGI(Y) by CBP turns off IFN beta expression by disrupting the enhanceosome. Mol Cell 1998;2: 457–467.PubMedGoogle Scholar
  56. 56.
    Vallone D, Battista S, Pierantoni GM, et al.: Neoplastic transformation of rat thyroid cells requires the junB and fra-1 gene induction which is dependent on the HMGI-C gene product. EMBO J 1997;16:5310–5321.PubMedGoogle Scholar
  57. 57.
    Thanos D, Maniatis T: The high mobility group protein HMG I(Y) is required for NF-kappa B-dependent virus induction of the human IFN-beta gene. Cell 1992;71:777–789.PubMedGoogle Scholar
  58. 58.
    Du W, Thanos D, Maniatis T: Mechanisms of transcriptional synergism between distinct virus-inducible enhancer elements. Cell 1993;74:887–898.PubMedGoogle Scholar
  59. 59.
    Thanos D, Maniatis T: Identification of the rel family members required for virus induction of the human beta interferon gene. Mol Cell Biol 1995;15:152–164.PubMedGoogle Scholar
  60. 60.
    Carey M: The enhanceosome and transcriptionalsynergy. Cell 1998;92:5–8.PubMedGoogle Scholar
  61. 61.
    Nissen MS and Reeves R. Changes insuperhelicity are introduced into closed circular DNA by binding of high mobility group protein I/Y. J Biol Chem 1995;270:4355–4360.PubMedGoogle Scholar
  62. 62.
    Arlotta P, Rustighi A, Mantovani F, et al.: High mobility groupl proteins interfere with the home-odomains binding to DNA. J Biol Chem 1997;272:29,904–29,910.Google Scholar
  63. 63.
    Falvo JV, Thanos D, Maniatis T: Reversal of intrinsic DNA bends in the IFN beta gene enhancer by transcription factors and the architectural protein HMG I(Y). Cell 1995;83:1101–1111.PubMedGoogle Scholar
  64. 64.
    Wolffe AP: Architectural transcription factors [comment]. Science 1994;264:1100–1101.PubMedGoogle Scholar
  65. 65.
    Yie J, Merika M, Munshi N, Chen G, Thanos D: The role of HMG I(Y) in the assembly and function of the IFN-beta enhanceosome. EMBO J 1999;18:3074–3089.PubMedGoogle Scholar
  66. 66.
    Bagga R, Michalowski S, Sabnis R, Griffith JD, Emerson BM: HMG I/Y regulates long-range enhancer-dependent transcription on DNA and chromatin by changes in DNA topology. Nucleic Acids Res 2000;28:2541–2550.PubMedGoogle Scholar
  67. 67.
    Yie J, Liang S, Merika M, Thanos D: Intra- and intermolecular cooperative binding of high-mobility-group protein I (Y) to the beta-interferon promoter. Mol Cell Biol 1997;17:3649–3662.PubMedGoogle Scholar
  68. 68.
    Merika M, Williams AJ, Chen G, Collins T, Thanos D: Recruitment of CBP/p300 by the 1FN beta enhanceosome is required for synergistic activation of transcription. Mol Cell 1998;1:277–287.PubMedGoogle Scholar
  69. 69.
    Kim TK, Kim TH, Maniatis T: Efficient recruitment of TFHB and CBP-RNA polymerase H holoenzyme by aninterferon-betaenhanceosome in vitro. Proc Natl Acad Sci USA 1998;95:12,191–12,196.Google Scholar
  70. 70.
    John S, Reeves RB, Lin JX, et al.: Regulation of cell-type-specific interleukin-2 receptoralpha-chain gene expression: potential role of physical interactions between Elf-1, HMG-I(Y), and NF-kappa B family proteins. Mol Cell Biol 1995;15:1786–1796.PubMedGoogle Scholar
  71. 71.
    Serfling E, Avots A, Neumann M: The architecture of the interleukin-2 promoter: a reflection of T lymphocyte activation. Biochim Biophys Acta 1995;1263:181–200.PubMedGoogle Scholar
  72. 72.
    Reeves R, Leonard WJ, Nissen MS: Binding of HMG-1(Y) imparts architectural specificity to a positioned nucleosome on the promoter of the human interleukin-2 receptor alpha gene. Mol Cell Biol 2000;20:4666–4679.PubMedGoogle Scholar
  73. 73.
    Abdulkadir SA, Krishna S, Thanos D, Maniatis T, Strominger JL, Ono SJ: Functional roles of the transcription factor Oct-2A and the high mobility group protein 1/Y in HLA-DRA gene expression. J Exp Med 1995;182:487–500.PubMedGoogle Scholar
  74. 74.
    Leger H, Sock E, Renner K, Grummt F, Wegner M: Functional interaction between the POU domain protein Tst-1/Oct-6 and the high-mobility-group protein HMG-I/Y. Mol Cell Biol 1995;15:3738–3747.PubMedGoogle Scholar
  75. 75.
    Thanos D, Maniatis T: Virusinduction of human IFN beta gene expression requires the assembly of anenhanceosome. Cell 1995;83:1091–1100.PubMedGoogle Scholar
  76. 76.
    Maniatis T, Falvo JV, Kim TH, et al.: Structure and function of the interferon-beta enhanceosome. Cold Spring Harb Symp Quant Biol 1998;63:609–620.PubMedGoogle Scholar
  77. 77.
    Bomefoy E, Bandu MT, Doly J: Specific binding of high-mobility-group 1 (HMGI) protein and histone H1 to the upstream AT-rich region of the murine beta interferon promoter: HMGI protein acts as a potential antirepressor of the promoter. Mol Cell Biol 1999;19:2803–2816.Google Scholar
  78. 78.
    Lewis H, Kaszubska W, DeLamarter JF, Whelan J: Cooperativity between two NF-kappa B complexes, mediated by high-mohility-group protein 1(Y), is essential for cytokine-induced expression of the E-selectin promoter. Mol Cell Biol 1994;14:5701–5709.PubMedGoogle Scholar
  79. 79.
    Whitley MZ, Thanos D, Read MA, Maniatis T, Collins T: A striking similarity in the organization of the E-selectin and be tainterferongene promoters. Mol Cell Biol 1994;14:6464–6475.PubMedGoogle Scholar
  80. 80.
    John S, Robbins CM, Leonard WJ: An IL-2 response element in the human IL-2 receptor alpha chain promoter is a composite element that binds Stat5, Elf-1, HMG-1(Y) and a GATA family protein. EMBO J 1996;15:5627–5635.PubMedGoogle Scholar
  81. 81.
    Himes SR, Coles LS, Reeves R, Shannon MF: High mobility group protein I(Y) is required for function and forc-Rel binding to CD28 response elements within the GM-CSF and IL-2 promoters. Immunity 1996;5:479–489.PubMedGoogle Scholar
  82. 82.
    Himes SR, Reeves R, Attema J, Nissen M, Li Y, Shannon MF: The role of high-mobility group 1(Y) proteins in expression of IL-2 and T cell proliferation. J Immunol 2000;164:3157–3168.PubMedGoogle Scholar
  83. 83.
    Wood LD, Richmond A: Constitutive and cytokine-induced expression of the melanoma growth stimulatory activity/GRO alpha gene requires both NF-kappa B and novel constitutive factors. J Biol Chem 1995;270:30,619–30,626.Google Scholar
  84. 84.
    Abdulkadir SA, Ono SJ: How are class 11 MHC genes turned on and off? Faseb J 1995;9:1429–1435.PubMedGoogle Scholar
  85. 85.
    Abdulkadir SA, Casolaro V, Tai AK, Thanos D, Ono SJ: High mobility group I/Y protein functions as a specific cofactor for Oct-2A: mapping of interaction domains. J Leukoc Biol 1998;64:681–691.PubMedGoogle Scholar
  86. 86.
    Khodadoust MM, Khan KD, Park EH, Bothwell AL: Distinct regulatory mechanisms for interferonal pha/beta (IFN-alpha/beta)- and IFN-gamma-mediated induction of Ly-6E gene in B cells. Blood 1998;92:2399–2409.PubMedGoogle Scholar
  87. 87.
    Khodadoust MM, Khan KD, Bothwell AL: Complex regulation of Ly-6E gene transcription in T cells by IFNs. J Immunol 1999;163:811–819.PubMedGoogle Scholar
  88. 88.
    Lokuta MA, Maher J, Noe KH, Pitha PM, Shin ML, Shin HS: Mechanisms of murine RANTES chemokine gene induction by Newcastle disease virus. J Biol Chem 1996;271:13,731–13,738.Google Scholar
  89. 89.
    Perrella MA, Pellacani A, Wiesel P, et al.: High mobility group-I(Y) protein facilitates nuclear factorkappaB bining and transactivation of the inducible nitric-oxide synthase promoter/enhancer. J Biol Chem 1999;274:9045–9052.PubMedGoogle Scholar
  90. 90.
    Foster LC, Wiesel P, Huggins GS, et al.: Role of activating protein-1 and high mobility group-I(Y) protein in the induction of CD44 gene expression by interleukin-1 beta in vascular smooth muscle cells. FASEB J 2000;14:368–378.PubMedGoogle Scholar
  91. 91.
    Fashena SJ, Reeves R, Ruddle NH: A poly(dA-dT) upstream activating sequence binds high-mobility group I protein and contributes to lymphotox in (tumor necrosis factor-beta) gene regulation. Mol Cell Biol 1992;12:894–903.PubMedGoogle Scholar
  92. 92.
    Skalnik DG, Neufeld EJ: Sequencespecific binding of HMG-I(Y) to the proximal promoter of the gp91-phox gene [published erratum appears in Biochem Biophys Res Commun 1993;190(1):308–309]. Biochem Biophys Res Commun 1992;187:563–569.PubMedGoogle Scholar
  93. 93.
    Skalnik DG, Neufeld EJ: Sequence-specific binding of HMG-1 (Y) to the proximal promoter of the gp91-phox gene. Biochem Biophys Res Commun 1993;190:308–309.PubMedGoogle Scholar
  94. 94.
    Shang C, Attema J, Cakouros D, Cockerill PN, Shannon MF: Nuclear factor of activated T cells contributes to the function of the CD28 response region of the granulocyte macrophage-colony stimulating factor promoter. Int Immunol 1999;11:1945–1956.PubMedGoogle Scholar
  95. 95.
    Chau K, Munshi N, Keane-Myers A, et al.: The architectural transcription factor HMG1(Y) participates in photoreceptor-specific gene expression. Journal of Neuroscience 2000;20:7317–7324.PubMedGoogle Scholar
  96. 96.
    Klein-Hessling S, Schneider G, Heinfling A, Chuvpilo S, Serfling E: HMG I(Y) interferes with the DNA binding of NF-AT factors and the induction of the interleukin 4 promoter in T cells. Proc Natl Acad Sci USA 1996;93:15,311–15,316.CrossRefGoogle Scholar
  97. 97.
    Wang DZ, Ray P, Boothby M: Interleukin 4-inducible phosphorylation of HMG-I(Y) is inhibited by rapamycin. J Biol Chem 1995; 270:22,924–22,932.Google Scholar
  98. 98.
    Kim J, Reeves R, Rothman P, Boothby M: The non-histone chromosomal protein HMG-I(Y) contributes to repression of the immunoglobulin heavy chain germ-line epsilon RNA promoter. Eur J Immunol 1995;25:798–808.PubMedGoogle Scholar
  99. 99.
    Bagga R, Emerson BM: An HMG 1/Y-containing repressor complex and supercoiled DNA topology are critical for long-range enhancer-dependent transcription in vitro. Genes Dev 1997;11:629–639.PubMedGoogle Scholar
  100. 100.
    Liberati C, Sgarra R, Manfioletti G, Mantovani R: DNA binding of NF-Y; the effect of HMGI proteins depends upon the CCAAT box. FEBS Lett 1998;433:174–178.PubMedGoogle Scholar
  101. 101.
    Currie RA: Functional interaction between the DNA binding subunit trimerization domain of NF-Y and the high mobility group protein HMG-I(Y). J Biol Chem 1997;272:30,880–30,888.Google Scholar
  102. 102.
    Lopez S, Reeves R, Island ML, et al.: Silencer activity in the interferon-A gene promoters. J Biol Chem 1997;272:22,788–22,799.Google Scholar
  103. 103.
    Ghersa P, Whelan J, Cambet Y, DeLamarter JF, Hooft van Huijsduijnen R: Distamycin prolongs E-selectin expression by interacting with a specific NF-kappaB-HMG-I (Y) binding site in the promoter. Nucleic Acids Res 1997;25:339–346.PubMedGoogle Scholar
  104. 104.
    Vartiainen E, Palvimo J, Mahonen A, Linnala-Kankkunen A, Maenpaa PH: Selective decrease in low-Mr HMG proteins HMG I and HMG Y during differentiation of mouse teratocarcinomacells [published erratum appears in FEBS Lett 1989;251 (1–2):283]. FEBS Lett 1988;228:45–48.PubMedGoogle Scholar
  105. 105.
    Rogalla P, Drechsler K, Frey G, et al.: HMGI-C expression patterns in human tissues. Implications for the genesis of frequnt mesenchymal tumors. Am J Pathol 1996; 149:775–779.PubMedGoogle Scholar
  106. 106.
    Beaujean N, Bouniol-Baly C, Monod C, et al.: Induction of early transcription in one-cell mouse embryos by microijection of the nonhistone chromosomal protein HMG-1. Dev Biol 2000;221:337–354.PubMedGoogle Scholar
  107. 107.
    Chiappetta G, Bandiera A, Berlingieri MT, et al.: The expression of the high mobility group HMGI (Y) proteinscorrelates with the malignant phenotype of human thyroid neoplasias. Oncogene 1995;10:1307–1314.PubMedGoogle Scholar
  108. 108.
    Zhou X, Benson KF, Przybysz K, et al.: Genomic structure and expression of the murine Hmgi-c gene. Nucleic Acids Res 1996;24:4071–4077.PubMedGoogle Scholar
  109. 109.
    Arlotta P, Tai AK, Manfioletti G, Clifford C, Jay G, Ono SJ: Transgenic mice expressing a truncated form of the high mobility gorup I-C protein develop dipsoity and an abnormally high prevalence of lipomas. J Biol Chem 2000;275:14,394–14,400.Google Scholar
  110. 110.
    Giancotti V, Berlingieri MT, DiFiore PP, Fusco A, Vecchio G, Crane-Robinson C: Changes in nuclear proteinson transformation of rat epithelial thyroid cells by a murinesarcoma retrovirus. Cancer Res 1985;45:6051–6057.PubMedGoogle Scholar
  111. 111.
    Giancotti V, Pani B, D'Andrea P, et al.: Elevated levels of a specific class of nuclear phosphoproteins incells transformed with v-ras and v-mos onc ogenes and by cotransfection with c- myc and polyoma middle T genes. EMBO J 1987;6:1981–1987.PubMedGoogle Scholar
  112. 112.
    Giancotti V, Buratti E, Perissin L, et al.: Analysis of the HMGI nuclear proteins in mouse neoplastic cells induced by different procedures. Exp Cell Res 1989; 184:538–545.PubMedGoogle Scholar
  113. 113.
    Bussemakers MJ, van de Ven WJ, Debruyne FM, Schalken JA: Identification of high mobility group protein I(Y) as potential progression marker for prostate cancer by differentialhy bridization analysis. Cancer Res 1991;51:606–611.PubMedGoogle Scholar
  114. 114.
    Tamimi Y, van der Poel HG, Denyn MM, et al.: The reasedexpression of high mobility group protein I(Y) in high grade prostatic cancer determined by in situ hybridization. Cancer Res 1993;53:5512–5516.PubMedGoogle Scholar
  115. 115.
    Tamimi Y, van der Poel HG, Karthaus HF, Debruyne FM, Schalken JA: A retrospective study of high mobility group protein 1(Y) as progression marker for prostate cancer determined by in situ hybridization. Br J Cancer 1996; 74:573–578.PubMedGoogle Scholar
  116. 116.
    Ram TG, Reeves R, Hosick HL: Elevated high mobility group-1 (Y) gene expression is associated with progressive transformation of mouse mammary epithelial cells. Cancer Res 1993;53:2655–2660.PubMedGoogle Scholar
  117. 117.
    Rogalla P, Drechsler K, Kazmier-czak B, Rippe V, Bonk U, Bullerdiek J: Expression of HMGI-C, a member of the high mobility group protein family, inasubset of breast cancers: relationship to histologic grade. Mol Carcinog 1997;19: 153–156.PubMedGoogle Scholar
  118. 118.
    Williams AJ, Powell WL, Collins T, Morton CC: HMGI(Y) expression in human uterine leiomyomata. Involvement of another high-mobility group architectural factor in a benign, neoplasm [see comments]. Am J Pathol 1997;150: 911–918.PubMedGoogle Scholar
  119. 119.
    Bandiera A, Bonifacio D, Manfioletti G, et al.: Expression of HMG1(Y) proteins in squamous intraepithelial and invasive lesions of the uterine cervix. Cancer Res 1998;58:426–431.PubMedGoogle Scholar
  120. 120.
    Abe N, Watanabe T, Masaki T, et al.: Pancreatic duct cell carcinomas express high levels of high mobility group 1(Y) proteins. Cancer Res 2000;60:3117–3122.PubMedGoogle Scholar
  121. 121.
    Fedele M, Bandiera A, Chiappetta G, et al.: Human colorectal carcinomas express high levels of high mobility group HMGI(Y) proteins. Cancer Res 1996;56:1896–1901.PubMedGoogle Scholar
  122. 122.
    Giannini G, Di Marcotullio L, Ristori E, et al.: HMG1(Y) and HMGI-C genes are expressed in neuroblastoma cell lines and tumors and affect retinoic acid responsiveness. Cancer Res 1999;59:2484–2492.PubMedGoogle Scholar
  123. 123.
    Abe N, Watanabe T, Sugiyama M, et al.: Determination of high mobility group I(Y) expression level in colorectal neoplasias: a potential diagnostic marker. Cancer Res 1999;59:1169–1174.PubMedGoogle Scholar
  124. 124.
    Wood LJ, Maher JF, Bunton TE, Resar LM: The oncogenic properties of the HMG-1 gene family. Cancer Res 2000;60:4256–4261.PubMedGoogle Scholar
  125. 125.
    Berlingieri MT, Manfioletti G, Santoro M, et al.: Inhibition of HMG1-C prote in synthesis suppresses retrovirally induced neoplastic transformation of rat thyroid cells. Mol Cell Biol 1995;15:1545–1553.PubMedGoogle Scholar
  126. 126.
    Sandros J, Stenman G, Mark J: Cytogenetic and molecular observations in human and experimental salivary gland tumors [see comments]. Cancer Genet Cytogenet 1990;44:153–167.PubMedGoogle Scholar
  127. 127.
    Nilbert M, Heim S, Mandahl N, Floderus UM, Willen H, Mitelman F: Characteristic chromosome abnormalities, including rearrangements of 6p, del(7q), +12, and t(12;14), in 44 uterine leiomyomas. Hum Genet 1990;85:605–611.PubMedGoogle Scholar
  128. 128.
    Kazmierczak B, Wanschura S, Rommel B, Bartnitzke S, Bullerdiek J: Ten pulmonary chondroid hamartomas with chromosome 6p21 break points within the HMG-I(Y) gene or its immediate surroundings. J Natl Cancer Inst 1996;88:1234–1236.PubMedGoogle Scholar
  129. 129.
    Kazmierczak B, Rosigkeit J, Wanschura S, et al.: HMGI-C rearrangements as the molecular basis for the majority of pulmonary chondroid hamartomas: a survey of 30 tumors. Oncogene 1996;12: 515–521.PubMedGoogle Scholar
  130. 130.
    Bol S, Wanschura S, Thode B, et al.: An endometrial polyp with a rearrangement of HMGI-C underlying a complex cytogenetic rearrangement involving chromosomes 2 and 12 Cancer Genet Cytogenet 1996;90:88–90.PubMedGoogle Scholar
  131. 131.
    Tallini G, Dal Cin P, Rhoden KJ, et al.: Expression of HMGI-C and HMGI(Y) in ordinary lipoma and atypical lipomatous tumors: immunohistochemical reactivity correlates with karyotypic alterations. Am J Pathol 1997;151: 37–43.PubMedGoogle Scholar
  132. 132.
    Berner JM, Meza-Zepeda LA, Kools PF, et al.: HMGIC, the gene for an architectural transcription factor, isamplified and rearranged in a subset of human sarcomas. Oncogene 1997;14:2935–2941.PubMedGoogle Scholar
  133. 133.
    Kazmierczak B, Dal Cin P, Wanschura S, Bartnitzke S, Van den Berghe H, Bullerdiek J: Cloning and molecular characterization of part of anew gene fused to HMGIC in mesenchymal tumors. Am J Pathol 1998;152:431–435.PubMedGoogle Scholar
  134. 134.
    Dal Cin P, Wanschura S, Kazmierczak B, et al.: Amplification and expression of the HMGIC gene in a henignendome trial polyp. Genes Chromosomes Cancer 1998;22: 95–99.Google Scholar
  135. 135.
    Mandahl N, Heim S, Arheden K, Rydholm A, Willen H, Mitelman F: Three major cytogenetic subgroups can be identified among chromosomally abnormal solitary lipomas. Hum Genet 1988;79: 203–208.PubMedGoogle Scholar
  136. 136.
    Sreekantaiah C, Leong SP, Karakousis CP, et al.: Cytogenetic profile of 109 lipomas. Cancer Res 1991;51:422–433.PubMedGoogle Scholar
  137. 137.
    Schoenmakers EF, Wanschura S, Mols R, Bullerdiek J, Van den Berghe H, Van de Ven WJ: Recurrent rearrangements in the high mobility group protein gene, HMGI-C, in benignmesenchymal tumours. Nal Genel 1995;10: 436–444.Google Scholar
  138. 138.
    Kazmierczak B, Hennig Y, Wanschura S, et al.: Description of a novel fusion transcript between HMGI-C, a gene encoding for a member of the high mobility group proteins, and the mitochondrial aldehyde dehydrogenase gene. Cancer Res 1995;55:6038–6039.PubMedGoogle Scholar
  139. 139.
    Kurose K, Mine N, Doi D, et al.: Novel gene fusion of COX6C at 8q22-23 to HMGIC at 12q15 in a uterine leiomyoma. Genes Chromosomes Cancer 2000;27: 303–307.PubMedGoogle Scholar
  140. 140.
    Geurts JM, Schoenmakers EF, Roijer E, Astrom AK, Stenman G, van de Ven WJ: Identification of NFIB as recurrent translocation partner gene of HMGIC in pleomorphic adenomas. Oncogene 1998;16:865–872.PubMedGoogle Scholar
  141. 141.
    Geurts JM, Schoenmakers EF, Roijer E, Stenman G, Van de Ven WJ: Expression of reciprocal hybrid transcripts of HMGIC and FHIT in a pleomorphic adenoma of the parotid gland. Cancer Res 1997;57:13–17.PubMedGoogle Scholar
  142. 142.
    Petit MM, Schoenmakers EF, Huysmans C, Geurts JM, Mandahl N, Van de Ven WJ: LHFP, a novel translocation partner gene of HMGIC in a lipoma, is a member of a new family of LHFP-like genes. Genomics 1999;57:438–441.PubMedGoogle Scholar
  143. 143.
    Tkachenko A, Ashar HR, Meloni AM, Sandberg AA, Chada KK: Misex pression of disrupted HMGI architectural factors activates alternative pathways of tumorigenesis. Cancer Res 1997;57: 2276–2280.PubMedGoogle Scholar
  144. 144.
    Fedele M, Berlingieri MT, Scala S, et al.: Truncated and chimeric HMGI-C genes induce neoplastic transformation of NIH3T3 murine fibroblasts. Oncogene 1998;17: 413–418.PubMedGoogle Scholar
  145. 145.
    Battista S, Fidanza V, Fedele M, et al.: The expression of a truncated HMGI-C gene induces gigantism associated with lipomatosis. Cancer Res 1999;59:4793–4797.PubMedGoogle Scholar
  146. 146.
    Xiao S, Lux ML, Reeves R, Hudson TJ, Fletcher JA: HMGI(Y) activation by chromosome 6p21 rearrangements in multilineage mesenchymal cells from pulmonary hamartoma [comment]. Am J Pathol 1997;150:901–910.PubMedGoogle Scholar
  147. 147.
    Rohen C, Rogalla P, Meyer-Bolte K, Bartnitzke S, Chilla R, Bullerdiek J: Pleomorphic adenomas of the salivary glands: absence of HMGIY rearrangements. Cancer Genet Cytogenet 1999; 111:178–181.PubMedGoogle Scholar
  148. 148.
    Sornberger KS, Weremowicz S, Williams AJ, et al.: Expression of HMGIY in three uterine leiomyomata with complex rearrangements of chromosome 6. Cancer Genet Cytogenet 1999;114:9–16.PubMedGoogle Scholar
  149. 149.
    Blank C, Rogalla P, Tran KH, Bullerdiek J: A novel high mobility group prote in gene is a candidate for Xp22 abnormalities in uterine leiomyomas and other benign tumors [In Process Citation]. Cancer Genet Cytogenet 2000;121:172–180.PubMedGoogle Scholar
  150. 150.
    Rogalla P, Kazmierczak B, Flohr AM, Hauke S, Bullerdiek J: Back to the roots of a new exon—the moleculararc haeology of a SP100 splice variant. Genomics 2000;63: 117–122.PubMedGoogle Scholar
  151. 151.
    Anand A, Chada K: In vivo modulation of Hmgic reduces obesity. Nat Genet 2000;24:377–380.PubMedGoogle Scholar
  152. 152.
    Chau K, Arlotta P, Patel UA, Crane-Robinson C, Manfioletti G, Ono SJ: A novel downstream positive regulatory element mediatingtranscription of the human high mobility group (HMG) I-C gene. FEBS Lett 1999;457:429–436.PubMedGoogle Scholar

Copyright information

© Humana Press Inc 2001

Authors and Affiliations

  • Franklin Liu
    • 1
  • Kai-yin Chau
    • 1
  • Paola Arlotta
    • 1
  • Santa Jerenry Ono
    • 1
  1. 1.University College London Institute of OphthalmologyUniversity of LondonLondonUK

Personalised recommendations